Effect of Suicidality on Social Cognition

Major Depressive Disorder Clinical Trial

Official title:

Effect of Suicidality in Major Depressive Disorder During Social Cognition

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06163612
• Other study ID #: 21-333
• Status: Recruiting
• Start date: September 1, 2022
• Est. completion date: December 31, 2024

Study information

• Verified date: May 2024
• Source: Unity Health Toronto
• Contact: Katharine Dunlop, PhD
• Phone: 416-864-6060
• Email: katharine.dunlop[@]unityhealth.to
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Major Depressive Disorder (MDD) is a very common illness that is usually treated with antidepressant medication. Depression can be caused by many things such as childhood experiences, genetics, and changes in the way the body and brain function. It is most likely caused by a combination of several of these factors. The prevalence of suicide attempt in Major Depressive Disorder (MDD) is about 20%. Risk for suicide attempt can be increased by many things such as negative life events, genetics, and changes in the way the body and brain function. It is most likely caused by a combination of several of these factors. In this study, the investigators will be collecting detailed information about participants' psychiatric history and depression symptoms, as well as brain scans. The goal is to use this information to help us determine what predicts suicide attempt history.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 150
• Est. completion date: December 31, 2024
• Est. primary completion date: December 31, 2024
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

3.2 Inclusion Criteria

Depressed Participants:

1. Between the ages of 18 and 65 years old.

2. Capable of giving voluntary and informed consent.

3. Fluent in English.

4. Meet DSM-5 criteria for single or recurrent Major Depressive Disorder (current major depressive episode), confirmed via the Mini-International Neuropsychiatric Interview (MINI 6.086).

5. Moderate to severe depression severity, defined as a 17-item Hamilton Depression Rating Scale87 score = 17.

6. Have had no initiation or dose change in any psychotropic medication in the four weeks prior to screening, as confirmed by the Antidepressant Treatment History Form (ATHF88).

7. If participating in psychotherapy, must have been in stable treatment for at least 3 months prior to entry into the study, with no anticipation of change in the frequency of therapeutic sessions, or the therapeutic focus over the duration of the study.

8. Can adhere to the study schedule.

9. Either a history of or no lifetime history of suicide attempt, confirmed via the Mini-International Neuropsychiatric Interview (MINI 6.086).

Nondepressed Participants:

1. Between the ages of 18 and 65 years old.

2. Capable of giving voluntary and informed consent.

3. Fluent in English.

4. No current or lifetime history of psychiatric diagnoses or suicidality, confirmed via the MINI 6.086.

5. Absent/non-clinical depression severity, defined as a 17-item Hamilton Depression Rating Scale87 < 8.

6. No history of antidepressant use, as measured by the ATHF88. 3.3 Exclusion Criteria

All Participants:

1. Are pregnant/lactating.

2. A MINI-confirmed diagnosis of major depressive disorder in people with bipolar disorder.

3. Other major medical comorbidities requiring immediate investigation or treatment, cardiac pacemaker, or implanted medication pump.

4. Lifetime history of psychosis, confirmed by the MINI 6.086, including schizophrenia, schizoaffective disorder, delusional disorder, or current psychotic symptoms.

5. Drug abuse or dependence within the last 6 months, excluding caffeine and nicotine.

6. Presence of contraindications for MRI, including metallic implants.

7. Have any significant neurological disorder or insult including, but not limited to:

any condition likely to be associated with increased intracranial pressure, space occupying brain lesion, any history of seizure except those therapeutically induced by ECT, cerebral aneurysm, Parkinson's disease, Huntington's chorea, multiple sclerosis, dementia, significant head trauma with loss of consciousness for greater than or equal to 5 minutes.

Related Conditions & MeSH terms

• Depression
• Depressive Disorder
• Depressive Disorder, Major
• Major Depressive Disorder
• Suicide

Intervention

Behavioral:
• Clinical Interview
A study team member will meet the participant to ask questions regarding the degree of depression at the beginning of the study. This interview will take approximately 1 hour.
• Clinical Questionnaires
A study team member will ask the participant to complete questionnaires assessing the severity of the participant's depression, daily activities, personality/traits, and quality of life. If the participant opts to complete these questionnaires at home, they will be emailed them within 24 hours of this visit. These questionnaires will take approximately 1-2 hours.

Other:
• Brain Scan
The participant will be asked to undergo a magnetic resonance imaging (MRI) scan to look at the structure and function of their brain. The functional MRI measures the level of blood flow to areas of the brain associated with mood and behaviour, and the participant will be asked to complete two behavioural games while they are in the scanner. During the scan, the participant will be required to lie on a table within the cylindrical tube of the MRI scanner in order to complete the scan. This will result in limited movement for the duration of the scan. The scan will take approximately 60 minutes.

Behavioral:
• Behavioural Games
The participant will be asked to complete two behavioural games inside the scanner. One of these games includes a monetary payout. They will be given instructions about these tasks outside of the scanner.

Locations

Country	Name	City	State
Canada	Unity Health Toronto	Toronto	Ontario

Sponsors (1)

Lead Sponsor	Collaborator
Unity Health Toronto

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	fMRI Markers for Suicide Risk	Potential fMRI brain activity for suicide risk using participants' brain scans	Through study completion, an average of 1 week